TriSalus Life Sciences Inc. - Asset Resilience Ratio
TriSalus Life Sciences Inc. (TLSI) has an Asset Resilience Ratio of 24.20% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how TriSalus Life Sciences Inc.'s Asset Resilience Ratio has changed over time. See financial agility of TriSalus Life Sciences Inc. to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down TriSalus Life Sciences Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see TLSI market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $60.60 Million | 24.2% |
| Total Liquid Assets | $60.60 Million | 24.20% |
Asset Resilience Insights
- Good Liquidity Position: TriSalus Life Sciences Inc. maintains a healthy 24.20% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
TriSalus Life Sciences Inc. Industry Peers by Asset Resilience Ratio
Compare TriSalus Life Sciences Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
T&R Biofab Co. Ltd
KQ:246710 |
Medical Devices | 0.12% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.48% |
|
Pulsenmore Ltd. Ordinary Shares
NASDAQ:PLSM |
Medical Devices | 46.67% |
|
Allmed Solutions Ltd
TA:ALMD |
Medical Devices | 80.03% |
|
Universal Biosensors Inc
AU:UBI |
Medical Devices | 14.72% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
Annual Asset Resilience Ratio for TriSalus Life Sciences Inc. (None–None)
The table below shows the annual Asset Resilience Ratio data for TriSalus Life Sciences Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemo… Read more